CASI - CASI Pharmaceuticals, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
3.7700
+0.1700 (+4.72%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close3.6000
Open3.6000
Bid0.00 x 1000
Ask0.00 x 3100
Day's Range3.6000 - 3.8300
52 Week Range2.7300 - 8.8900
Volume404,488
Avg. Volume343,206
Market Cap359.233M
Beta (3Y Monthly)1.60
PE Ratio (TTM)N/A
EPS (TTM)-0.30
Earnings DateMar 27, 2019 - Apr 1, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est7.00
Trade prices are not sourced from all markets
  • CASI Pharmaceuticals Announces China National Medical Products Administration (NMPA) Approval Of CTA To Conduct Confirmatory Clinical Trial For ZEVALIN®
    PR Newswire21 hours ago

    CASI Pharmaceuticals Announces China National Medical Products Administration (NMPA) Approval Of CTA To Conduct Confirmatory Clinical Trial For ZEVALIN®

    ROCKVILLE, Md. , Feb. 19, 2019 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. based pharmaceutical company with a platform to develop and accelerate the launch of pharmaceutical products ...

  • CASI Pharmaceuticals to Present at the BIO CEO & Investor Conference
    PR Newswire14 days ago

    CASI Pharmaceuticals to Present at the BIO CEO & Investor Conference

    ROCKVILLE, Md. , Feb. 6, 2019 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company dedicated to the development and delivery of high quality, cost-effective pharmaceutical ...

  • ACCESSWIRE2 months ago

    These 4 Healthcare Stocks Are Heating Up

    CORAL GABLES, FL / ACCESSWIRE / December 28, 2018 / The healthcare industry has shown tremendous growth over the last few months, as experts and professionals in the field have worked on developing technologies to improve the quality of care for patients on a global scale. From data-based approaches and analysis consumer demands/needs, advancements in the sector may catalyze potential opportunities for those looking to healthcare. Premier Health Group (OTC:PHGRF) (CSE:PHGI), Akers Biosciences Inc (AKER), CASI Pharmaceuticals Inc (CASI), and Rite Aid Corporation (RAD) represent 4 healthcare companies innovating towards the future. Premier Health Group (OTC:PHGRF) (CSE:PHGI) announced, earlier this month that as part of its overarching strategy to cover major verticals associated with primary care, it had signed into a binding Letter of Intent (LOI) agreement to acquire a Vancouver-based pharmacy.

  • Do Institutions Own Shares In CASI Pharmaceuticals, Inc. (NASDAQ:CASI)?
    Simply Wall St.2 months ago

    Do Institutions Own Shares In CASI Pharmaceuticals, Inc. (NASDAQ:CASI)?

    A look at the shareholders of CASI Pharmaceuticals, Inc. (NASDAQ:CASI) can tell us which group is most powerful. Institutions often own shares in more established companies, while it's not unusual Read More...

  • ACCESSWIRE3 months ago

    The 4 Healthcare Stocks To Watch On Monday

    CORAL GABLES, FL / ACCESSWIRE / December 3, 2018 / Attention on Healthcare Market has continued to accelerate this quarter. The global healthcare IT market is expected to post a CAGR of over 8% during the period 2018-2022, according to the latest market research report by Technavio.

  • CASI Pharmaceuticals Announces China Market Approval Of Melphalan Hydrochloride For Injection (Trademark: EVOMELA®)
    PR Newswire3 months ago

    CASI Pharmaceuticals Announces China Market Approval Of Melphalan Hydrochloride For Injection (Trademark: EVOMELA®)

    National Medical Products Administration Approves Melphalan Hydrochloride For Injection (EVOMELA®) as Treatment for Specific Uses in Patients with Multiple Myeloma ROCKVILLE, Md. , Dec. 3, 2018 /PRNewswire/ ...

  • Chinese biotech stocks hit by a double whammy, which means it’s time to buy
    MarketWatch3 months ago

    Chinese biotech stocks hit by a double whammy, which means it’s time to buy

    The decline in biotech stocks is more about investors fleeing a high-beta group in a risk-off environment.

  • GlobeNewswire3 months ago

    Report: Exploring Fundamental Drivers Behind CASI Pharmaceuticals, Booking, Enstar Group, Madrigal Pharmaceuticals, Dermira, and Kaiser Aluminum — New Horizons, Emerging Trends, and Upcoming Developments

    NEW YORK, Nov. 28, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • CASI Pharmaceuticals To Build GMP Manufacturing Site In Wuxi, China
    PR Newswire3 months ago

    CASI Pharmaceuticals To Build GMP Manufacturing Site In Wuxi, China

    The facility will be designed and constructed based on global cGMP requirements and is expected to have capacity for large scale production.  The facility will be a key asset supporting CASI's growth and commercialization plans with further agreements to be finalized and site construction to begin in mid-2019.

  • CASI Pharmaceuticals Announces Third Quarter and First Nine Months 2018 Financial and Business Results
    PR Newswire3 months ago

    CASI Pharmaceuticals Announces Third Quarter and First Nine Months 2018 Financial and Business Results

    - Key new hires include Chief Financial Officer and President, CASI China as CASI prepares for global commercialization efforts - Acquired U.S. FDA-approved abbreviated new drug application (ANDA) from ...

  • ACCESSWIRE4 months ago

    Today’s Research Reports on Stocks to Watch: CASI Pharmaceuticals and Therapix Biosciences

    NEW YORK, NY / ACCESSWIRE / October 24, 2018 / Biotech stocks CASI Pharmaceuticals and Therapix Biosciences were both seeing big gains on acquisition news. CASI has acquired a U.S. FDA-approved abbreviated ...

  • Why CASI Pharmaceuticals Inc. Is Rocketing Higher Today
    Motley Fool4 months ago

    Why CASI Pharmaceuticals Inc. Is Rocketing Higher Today

    Investors are pleased with a plan to sell generic Viread in China.

  • ACCESSWIRE4 months ago

    3 Healthcare Stocks Trending Higher On News

    Today, we're exploring 3 stocks to watch that are focusing on building their business in the health related markets including Premier Health Group, Inc. ( PHGRF)(PHGI.CN), Symbililty Solutions Inc. (TSX-V:SY.V)(OTC PINK: ATBEF), and CASI Pharmaceuticals, Inc. (CASI). Premier Health Group, Inc. (PHGRF)(PHGI.CN)’s subsidiary, HealthVue is focused on developing proprietary technology to deliver quality healthcare through the combination of connected primary care clinics with telemedicine and artificial intelligence. With new access to things like the telemedicine technology that HealthVue offers, the technology allows users to see virtual HealthVue doctor through the telemedicine app/website (Government funded in BC, therefore no additional cost to the patient).

  • CASI Pharmaceuticals Acquires HBV ANDA from Laurus Labs Limited
    PR Newswire4 months ago

    CASI Pharmaceuticals Acquires HBV ANDA from Laurus Labs Limited

    ROCKVILLE, Md., Oct. 23, 2018 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (CASI), a biopharmaceutical company dedicated to the development and delivery of high quality, cost-effective pharmaceutical products and innovative therapeutics to patients in China and throughout the world, announces that it has acquired a U.S. FDA-approved abbreviated new drug application (ANDA) from Laurus Labs Limited.  The drug, tenofovir disoproxil fumarate (TDF), is indicated for the treatment of hepatitis B virus (HBV). As part of the transaction, CASI will make certain upfront and milestone payments in different phases.  There are more than 90 million chronic carriers of hepatitis B in China which accounts for roughly one-third of all HBV chronic carriers in the world, with TDF currently as the first line therapy.

  • CASI Pharmaceuticals Announces Appointment Of President To Its China Operations To Lead Commercialization
    PR Newswire5 months ago

    CASI Pharmaceuticals Announces Appointment Of President To Its China Operations To Lead Commercialization

    ROCKVILLE, Md. , Oct. 2, 2018 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company dedicated to the development and delivery of high quality, cost-effective pharmaceutical ...

  • CASI Pharmaceuticals Announces Appointment Of Chief Financial Officer
    PR Newswire5 months ago

    CASI Pharmaceuticals Announces Appointment Of Chief Financial Officer

    ROCKVILLE, Md., Sept. 28, 2018 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (CASI), a biopharmaceutical company dedicated to the development and delivery of high quality, cost-effective pharmaceutical products and innovative therapeutics to patients in the U.S., China and throughout the world, announces the appointment of George Chi to the position of Chief Financial Officer. Dr. He continued, "George had been the key accountable person responsible for financial controls and regulatory filings in global companies with multiple divisions commercializing products in many countries including the U.S. and China.

  • CASI Pharmaceuticals Announces $48.5 Million Private Placement
    PR Newswire5 months ago

    CASI Pharmaceuticals Announces $48.5 Million Private Placement

    ROCKVILLE, Md., Sept. 14, 2018 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (CASI), a biopharmaceutical company dedicated to the development and delivery of high quality, cost-effective pharmaceutical products and innovative therapeutics to patients in the U.S., China and throughout the world, announces today a $48.5 million private placement. The Company has entered into definitive securities purchase agreements pursuant to which the Company will issue 9,048,504 shares of its Common Stock with accompanying warrants to purchase 2,714,548 shares of its Common Stock. The purchase price for each share of Common Stock and warrant is $5.36.

  • CASI Pharmaceuticals Announces Second Quarter And First Half 2018 Financial And Business Results
    PR Newswire6 months ago

    CASI Pharmaceuticals Announces Second Quarter And First Half 2018 Financial And Business Results

    - China FDA (CFDA) import drug registration priority review of EVOMELA® in progress and preparations continue for its commercial launch in China - CFDA review in progress for Marqibo® and Zevalin® - Entered ...

  • Benzinga8 months ago

    Benzinga's Daily Biotech Pulse: Realm Therapeutics To List On Nasdaq, CASI Pharma Added To Russell 2000 Index

    Here's a roundup of top developments in the biotech space since Tuesday morning. Scaling the Peaks (Stocks hitting 52-week highs on July 3) Arbutus Biopharma Corp (NASDAQ: ABUS ) Arrowhead Pharmaceuticals ...

  • CASI Pharmaceuticals Added To Russell 2000®, 3000® And Microcap® Indexes
    PR Newswire8 months ago

    CASI Pharmaceuticals Added To Russell 2000®, 3000® And Microcap® Indexes

    ROCKVILLE, Md., July 3, 2018 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (CASI), a biopharmaceutical company dedicated to the development and delivery of high quality, cost-effective pharmaceutical products and innovative therapeutics to patients in the U.S., China and throughout the world, announces that the company has been added to the Russell 2000®, 3000® and Microcap® Indexes, effective after U.S. market closed on Friday, June 22, 2018. For more information on the Russell Indexes and the Russell US Indexes reconstitution, please refer to the FTSE Russell website at http://www.ftserussell.com. CASI Pharmaceuticals (CASI) is a biopharmaceutical company dedicated to the development and delivery of high quality, cost-effective pharmaceutical products and innovative therapeutics to patients in the U.S., China and throughout the world.

  • Here's Why CASI Pharmaceuticals Rose as Much as 31.6% Today
    Motley Fool8 months ago

    Here's Why CASI Pharmaceuticals Rose as Much as 31.6% Today

    But it didn't last long.

  • CASI Pharmaceuticals Enters Strategic Partnering And Contract Manufacturing Agreement With Yiling Wanzhou International Pharmaceuticals For Entecavir And Cilostazol
    PR Newswire8 months ago

    CASI Pharmaceuticals Enters Strategic Partnering And Contract Manufacturing Agreement With Yiling Wanzhou International Pharmaceuticals For Entecavir And Cilostazol

    Agreement marks significant milestone for two of the 29 ANDAs acquired by CASI from Sandoz in January 2018 ROCKVILLE, Md. , June 21, 2018 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical ...